Since splice modulation AOs are coming of age with the recent approvals of Exondys 51 and Spinraza, we report splice modifying AOs that reduce ITGA4 activity, identified by in vitro screening and validated in vivo in a mouse model of MS. This evidence concerns the gene ITGA4 and myeloid sarcoma.